Jacques Dumas

5.2k total citations · 2 hit papers
46 papers, 3.9k citations indexed

About

Jacques Dumas is a scholar working on Molecular Biology, Organic Chemistry and Pharmaceutical Science. According to data from OpenAlex, Jacques Dumas has authored 46 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 17 papers in Organic Chemistry and 7 papers in Pharmaceutical Science. Recurrent topics in Jacques Dumas's work include Melanoma and MAPK Pathways (7 papers), Synthesis and biological activity (6 papers) and Fluorine in Organic Chemistry (6 papers). Jacques Dumas is often cited by papers focused on Melanoma and MAPK Pathways (7 papers), Synthesis and biological activity (6 papers) and Fluorine in Organic Chemistry (6 papers). Jacques Dumas collaborates with scholars based in United States, France and Germany. Jacques Dumas's co-authors include Scott M. Wilhelm, Mark Lynch, Roger A. Smith, Timothy B. Lowinger, Brian Schwartz, Ronit Simantov, Christopher Carter, Susan L. Kelley, Lila Adnane and Barry M. Trost and has published in prestigious journals such as Journal of the American Chemical Society, Nature Reviews Drug Discovery and FEBS Letters.

In The Last Decade

Jacques Dumas

44 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

2006 1.4k citations Scott M. Wilhelm, Christopher Carter et al. Nature Reviews Drug Discovery profile →
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

2010 1.0k citations Scott M. Wilhelm, Jacques Dumas et al. International Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacques Dumas United States	22	1.7k	1.1k	1.0k	614	564	46	3.9k
Roger A. Smith United States	21	1.4k 0.8×	704 0.6×	890 0.9×	297 0.5×	236 0.4×	60	2.8k
Timothy B. Lowinger United States	20	1.3k 0.8×	843 0.7×	742 0.7×	305 0.5×	262 0.5×	53	2.7k
Sylvie M. Guichard United Kingdom	33	2.3k 1.4×	1.6k 1.4×	555 0.5×	271 0.4×	319 0.6×	96	4.0k
Ralf A. Hilger Germany	27	1.3k 0.8×	1.2k 1.1×	285 0.3×	333 0.5×	618 1.1×	83	3.2k
Michele McTigue United States	18	1.7k 1.0×	1.0k 0.9×	388 0.4×	225 0.4×	438 0.8×	25	2.9k
Yasuhiro Funahashi Japan	37	2.4k 1.4×	2.1k 1.9×	603 0.6×	668 1.1×	1.0k 1.8×	117	6.0k
K. Mross Germany	37	2.1k 1.2×	3.1k 2.7×	311 0.3×	361 0.6×	1.0k 1.8×	148	5.2k
Mei‐Sze Chua United States	33	2.1k 1.2×	585 0.5×	698 0.7×	262 0.4×	231 0.4×	55	4.0k
Peter Traxler Switzerland	30	2.7k 1.6×	1.6k 1.4×	1.1k 1.1×	187 0.3×	465 0.8×	61	4.6k
Gerrit Los United States	33	1.8k 1.1×	1.7k 1.5×	236 0.2×	462 0.8×	1.0k 1.8×	94	4.1k

Countries citing papers authored by Jacques Dumas

Since Specialization

Citations

This map shows the geographic impact of Jacques Dumas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Dumas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Dumas more than expected).

Fields of papers citing papers by Jacques Dumas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Dumas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Dumas. The network helps show where Jacques Dumas may publish in the future.

Co-authorship network of co-authors of Jacques Dumas

This figure shows the co-authorship network connecting the top 25 collaborators of Jacques Dumas. A scholar is included among the top collaborators of Jacques Dumas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacques Dumas. Jacques Dumas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Michot, Nadine, et al.. (2022). Albumin binding Nanofitins, a new scaffold to extend half-life of biologics – a case study with exenatide peptide. Peptides. 152. 170760–170760. 9 indexed citations

Mathieu, Magali, Christine Hamel, Paul Ferrari, et al.. (2014). Structures of a pan‐specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody–antigen interactions. Protein Science. 23(12). 1698–1707. 22 indexed citations

Wilhelm, Scott M., Jacques Dumas, Lila Adnane, et al.. (2010). Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer. 129(1). 245–255. 1025 indexed citations breakdown →

Auclair, Daniel, David F. Miller, W C Pickett, et al.. (2007). Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 21(3). 439–445. 134 indexed citations

Wilhelm, Scott M., Christopher Carter, Mark Lynch, et al.. (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery. 5(10). 835–844. 1447 indexed citations breakdown →

Smith, Roger A., Jacques Dumas, Lila Adnane, & Scott M. Wilhelm. (2006). Recent Advances in the Research and Development of RAF Kinase Inhibitors. Current Topics in Medicinal Chemistry. 6(11). 1071–1089. 37 indexed citations

Dumas, Jacques, et al.. (2005). VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures. Expert Opinion on Therapeutic Patents. 15(6). 647–658. 21 indexed citations

Lara, Beatriz, Ana Isabel Rico, Sabrina Petruzzelli, et al.. (2004). Cell division in cocci: localization and properties of the Streptococcus pneumoniae FtsA protein. Molecular Microbiology. 55(3). 699–711. 105 indexed citations

Sibley, Robert, Holia Hatoum‐Mokdad, Robert Schoenleber, et al.. (2003). A novel estrogen receptor ligand template. Bioorganic & Medicinal Chemistry Letters. 13(11). 1919–1922. 31 indexed citations

10.

Smith, Roger A., et al.. (2001). Discovery and parallel synthesis of a new class of cathepsin k inhibitors. Bioorganic & Medicinal Chemistry Letters. 11(22). 2951–2954. 11 indexed citations

11.

Dumas, Jacques, Robert Sibley, Bernd Riedl, et al.. (2000). Discovery of a new class of p38 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(18). 2047–2050. 34 indexed citations

12.

Dumas, Jacques, Holia Hatoum‐Mokdad, Robert Sibley, et al.. (2000). 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 10(18). 2051–2054. 47 indexed citations

13.

Dumas, Jacques, David R. Brittelli, Jinshan Chen, et al.. (1999). Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorganic & Medicinal Chemistry Letters. 9(17). 2531–2536. 82 indexed citations

14.

Brun, G, Florina Moldovan, Jean‐Marie Villette, et al.. (1997). Sandwich-type enzyme immunoassay for big endothelin-1 in plasma: concentrations in healthy human subjects unaffected by sex or posture. Clinical Chemistry. 43(1). 64–70. 12 indexed citations

15.

Moldovan, Florina, et al.. (1996). Establishment of permanent human endothelial cells achieved by transfection with SV40 large T antigen that retain typical phenotypical and functional characteristics. In Vitro Cellular & Developmental Biology - Animal. 32(1). 16–23. 5 indexed citations

16.

Moldovan, Florina, et al.. (1995). [Functional properties of a new line of immortalized human endothelial cells].. PubMed. 318(9). 951–8. 2 indexed citations

17.

Trost, Barry M. & Jacques Dumas. (1993). On the regioselectivity of Pd catalyzed intramolecular carbametalations. Tetrahedron Letters. 34(1). 19–22. 31 indexed citations

18.

Gravier‐Pelletier, Christine, Jacques Dumas, Yves Le Merrer, & Jean‐Claude Depezay. (1992). Lipoxins A4 and B4 Total Synthesis Including Deprotection Studies. Tetrahedron. 48(12). 2441–2452. 11 indexed citations

19.

Merrer, Yves Le, Christine Gravier‐Pelletier, Jacques Dumas, & Jean‐Claude Depezay. (1990). Chiral α-hydroxy- and α,β-dihydroxy- aldehydes from D-isoascorbic and L-ascorbic acids. Useful precursors for the synthesis of fatty acid metabolites.. Tetrahedron Letters. 31(7). 1003–1006. 24 indexed citations

20.

Dumas, Jacques, et al.. (1955). [Role of peroxides in the genesis of lesions produced by radiations].. PubMed. 36(5-6). 343–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact